To save the patient during an infarction, the recommendations are to re-open (reperfuse) the occluded artery as quickly as possible (angioplasty or thrombolysis). However, despite optimal patient management, mortality and morbidity rates (particularly for heart failure) are still too high.

To face this major public health problem, ApoRepair has developed a therapeutic molecule – the Tat-DAXXp peptide – for all heart attack patients, to be administered as an adjunct to artery reopening.